Prilenia Neurotherapeutics Ltd.

Auspex Pharmaceuticals, Inc.

Ralph Laufer

Michal Geva

Michael Hayden

Chengzhi Zhang

Aric Orbach

Hermann Kurt Russ

Neta Zach

The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.

Use of pridopidine for treating rett syndrome

The subject invention provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject.

Treatment of neurodegenerative eye disease using pridopidine

Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.

Method of treating amyotrophic lateral sclerosis with pridopidine

Described are deuterium-substituted tetrahydrocarbazole compounds of Formulae I, II, or III which are inhibitors of sirtuin 1 (SIRT1). Also described are pharmaceutical compositions comprising the deuterium-substituted tetrahydrocarbazole compounds, and methods of use thereof. 

Growing community of inventors

Tel Aviv, Israel

Ralph Laufer